Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, Stage IIIB-IV nonsmall cell lung cancer

Cancer

Volumn 107, Issue 5, 2006, Pages 1050-1054

  Akerley, Wallace ^a   Safran, Howard ^b   Zaner, Ken ^c   Ready, Neal ^b   Mega, Tony ^b   Kennedy, Teresa ^b  

^a UNIVERSITY OF UTAH   (United States)

^b Brown University Oncology Group   (United States)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gemcitabine; Lung cancer; Paclitaxel; Pneumonitis; Weekly schedule

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; GEMCITABINE; PACLITAXEL; RANITIDINE; STEROID;

ADULT; AGED; ALOPECIA; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD CELL COUNT; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; INTERSTITIAL PNEUMONIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; METASTASIS; MYALGIA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STEROID THERAPY; SURVIVAL RATE; SURVIVAL TIME; THORAX RADIOGRAPHY; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; PACLITAXEL; SALVAGE THERAPY; SURVIVAL RATE;

EID: 33747881726     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22095     Document Type: Article

References (23)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative Group. Br Med J. 1995;311:899-909.
3. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus nonplatinum-based chemotherapy in non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23:2926-2936.
4. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993;85:384-388.
5. Chang AY, Kim K, Glick J, et al. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group Results. J Natl Cancer Inst. 1993;85:388-394.
6. Bonomi P, Kim K, Kusler J, et al. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Oncology (Huntingt). 1997;11:9-10.
7. Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol. 1994;12:2682-2686.
8. Akerley W, Glantz M, Choy H, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol. 1998;16:153-158.
9. Akerley W, Choy H, Safran H, et al. Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin Oncol. 1997;24:S12-10-S12-13.
10. Akerley W, Herndon J, Egorin M, et al. Weekly high-dose paclitaxel in advanced lung carcinoma: a phase II trial with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003;97:2480-2486.
11. Chang AY, Rubins J, Asbury R, Boros L, Hui LF. Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol. 2001;4(Suppl 14):10-13.
12. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491-498.
13. Manegold C, Bergman B, Chemaissani A, et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomized phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol. 1997;8:525-529.
14. Lara PN Jr., Gumerlock PH, Mack PC, et al. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer. 2004;6:102-107.
15. Aggarwal L, Akerley W, Wingate P, et al. Weekly paclitaxel-effect on platelets in patients with NSCLC and in patients with prostate cancer and thrombocytopenia [#202]. Proc Am Soc Clin Oncol. 1998;17:52a.
16. Pertusini E, Ratajczak J, Majka M, et al. Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood. 2001;97:638-644.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
18. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2002;20:3578-3585.
19. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced nonsmall-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol. 2003;21:3909-3917.
20. Bhatia S, Hanna N, Ansari R, et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer (Amster). 2002;38:73-77.
21. Chen YM, Perng RP, Lin WC, et al. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol. 2002;25:509-512.
22. Popa IE, Stewart K, Smith FP, et al. A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma. Cancer. 2002;95:1714-1719.
23. Thomas AL, Cox G, Sharma RA, et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose escalating study. Eur J Cancer. 2000;36:2329-2334.